Free Newsletter
Merck, Schering to combine blockbusters
Why not build on success? Schering-Plough and Merck are asking the FDA to approve a pill that combines the active ingredients of Singulair, the blockbuster asthma-and-allergy remedy, and Claritin, another best-selling allergy drug that went generic and over-the-counter in 2002. Under development by a joint venture of the two companies, the new product has been accepted for the FDA's standard review process.
- see the release on the combination package
Related Articles:
Drug combos not a sure thing. Report
New combos of old drugs may be boon to biotech. Report
New combo cholesterol drug being planned. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: